Definium Therapeutics, Inc. (NASDAQ:DFTX)
| Market Cap | 5.16B+303.0% |
| Revenue (ttm) | 0 |
| Net Income | -353.79M-208.9% |
| EPS | -3.43-139.9% |
| Shares Out | 132.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,449,199 |
| Open | 37.73 |
| Previous Close | 37.73 |
| Day's Range | 37.73 - 39.37 |
| 52-Week Range | 12.88 - 49.20 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | 64.90(+66.88%) |
| Earnings Date | Nov 5, 2026 |
About DFTX
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DFTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DFTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DFTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DFTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DFTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DFTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DFTX
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $125.72M |
| VXFVanguard Extended Market ETF | $65.02M |
| IWOiShares Russell 2000 Growth ETF | $46.41M |
| IBBiShares Biotechnology ETF | $36.92M |
| VTWOVanguard Russell 2000 ETF | $31.78M |
| SCHASchwab U.S. Small-Cap ETF | $23.33M |
Estimated from each fund’s disclosed top holdings × AUM
DFTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DFTX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score